- Home
- JZXN vs SNTI Comparison
JZXN vs SNTI Comparison
Compare JZXN & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JZXN
- SNTI
- Stock Information
- Founded
- JZXN 2017
- SNTI 2016
- Country
- JZXN China
- SNTI United States
- Employees
- JZXN N/A
- SNTI N/A
- Industry
- JZXN Retail-Auto Dealers and Gas Stations
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- JZXN Consumer Discretionary
- SNTI Health Care
- Exchange
- JZXN Nasdaq
- SNTI Nasdaq
- Market Cap
- JZXN 15.3M
- SNTI 14.1M
- IPO Year
- JZXN 2021
- SNTI N/A
- Fundamental
- Price
- JZXN $1.31
- SNTI $2.19
- Analyst Decision
- JZXN
- SNTI
- Analyst Count
- JZXN 0
- SNTI 0
- Target Price
- JZXN N/A
- SNTI N/A
- AVG Volume (30 Days)
- JZXN 26.9K
- SNTI 23.2K
- Earning Date
- JZXN 10-15-2024
- SNTI 11-11-2024
- Dividend Yield
- JZXN N/A
- SNTI N/A
- EPS Growth
- JZXN N/A
- SNTI N/A
- EPS
- JZXN N/A
- SNTI N/A
- Revenue
- JZXN $7,597,423.00
- SNTI $338,000.00
- Revenue This Year
- JZXN N/A
- SNTI $254.47
- Revenue Next Year
- JZXN N/A
- SNTI $169.66
- P/E Ratio
- JZXN N/A
- SNTI N/A
- Revenue Growth
- JZXN 81.94
- SNTI N/A
- 52 Week Low
- JZXN $1.00
- SNTI $1.52
- 52 Week High
- JZXN $67.60
- SNTI $8.48
- Technical
- Relative Strength Index (RSI)
- JZXN 39.30
- SNTI 39.08
- Support Level
- JZXN $1.36
- SNTI $2.08
- Resistance Level
- JZXN $1.76
- SNTI $2.56
- Average True Range (ATR)
- JZXN 0.17
- SNTI 0.24
- MACD
- JZXN -0.01
- SNTI -0.04
- Stochastic Oscillator
- JZXN 4.84
- SNTI 10.57
About JZXN Jiuzi Holdings Inc.
Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It sells new energy vehicles in third-fourth tier cities in China. The firm also sells plug-in electric vehicles on demand from vehicle buyers. Its business segments are sales of NEVs and Franchisees services. The company generates a majority of its revenue from the NEVs segment. Geographically, the firm operates in China.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.